Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Case Reports1
- Research Support, U.S. Gov't, Non-P.H.S.1
- Research Support, U.S. Gov't, P.H.S.1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- J Clin Invest1
Search Results
Sort by
- Bookeditors Richard A. Rudick, Robert A. Bermel.Contents:
Addressing unmet medical needs in RR-MS / Robert A. Bermel & Richard A. Rudick
Current guidelines and standard treatments of RR-MS / R. Philip Kinkel & Augusto Miravalle
Oral agents for the treatment of RR-MS / Douglas R. Jeffery
Monoclonal antibodies / Jennifer Graves & Emmanuelle L. Waubant
Other therapeutics in the pipeline and future directions / Yuval Karmon, Bijal K. Mehta & Bianca Weinstock-Guttman. - ArticleDonofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J.J Clin Invest. 1978 Oct;62(4):884-7.The deoxynucleotide, dATP, is elevated 50- to 1,000-fold above normal in erythrocytes, lymphocytes, and bone marrow from a child with adenosine deaminase deficiency and severe combined immunodeficiency disease. The child, when 17 mo of age, was also excreting approximately 30 mg of deoxyadenosine per day in urine (normal is less than 0.1 mg/day). Urinary excretion of uric acid was decreased. Elevated dATP levels in lymphocytes and bone marrow, and increased urinary excretion of deoxyadenosine, persisted despite hypertransfusion of the child with irradiated erythrocytes from a donor with normal adenosine deaminase. Overproduction of deoxynucleotides by increased salvage of adenosine appears to be the primary metabolic abnormality in patients with adenosine de aminase deficiency.